DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Live feed of FDA warning letters, MDL lawsuits, recalls, and safety communications. Most affiliate sites hide this. We surface it — for the same reason we publish editorial coverage and methodology.
Subject: Novo Nordisk
Multidistrict Litigation (MDL) consolidating claims of NAION vision loss linked to semaglutide use. As of May 2026, 86 plaintiffs alleging permanent vision loss after Ozempic or Wegovy treatment.
What you should do
If you experience sudden vision loss while on semaglutide, seek immediate ophthalmology evaluation. Patients with diabetes-related eye disease should discuss NAION risk with prescriber before starting.
Subject: Novo Nordisk + Eli Lilly
Largest active MDL for GLP-1 medications, alleging failure to warn about gastroparesis and severe GI complications. 3,636 plaintiffs across all major brands as of May 2026.
What you should do
Severe persistent vomiting or inability to keep food down on a GLP-1 = stop immediately and seek emergency care. May be reversible if caught early.
Subject: Novo Nordisk
Novo Nordisk voluntarily recalled three lots of Wegovy Pill (oral semaglutide 25mg) due to substandard tablet dissolution rates affecting bioavailability.
Action: Check your Wegovy Pill bottle lot number. If affected, contact your pharmacy for replacement at no charge. Do not stop treatment abruptly — replace with new lot.
Source: FDA.gov RecallsSubject: Eli Lilly
FDA updated tirzepatide (Mounjaro, Zepbound) labeling to strengthen pancreatitis warning following 47 post-market acute pancreatitis reports in 2025.
Action: Severe persistent abdominal pain on Mounjaro or Zepbound = stop immediately and seek emergency care. Pancreatitis is medical emergency.
Source: FDA.govSubject: Mochi Health
FDA cited Mochi for sourcing compounded tirzepatide from 503A pharmacies after FDA declared the shortage resolved, requiring justification under "personalized formulation" doctrine.
Action: Compounded tirzepatide users should expect potential supply disruption Q3-Q4 2026 as enforcement proceeds. Have a transition plan to Zepbound/Mounjaro if eligible.
Source: Frier LevittSubject: Empower Pharmacy
FDA cited Empower Pharmacy for failure to maintain cGMP standards in compounded semaglutide and tirzepatide production, including inadequate sterility testing.
Action: Current Empower compounded patients should verify supply chain with prescriber and consider transition to FDA-approved alternatives if available.
Source: FDA.govSubject: Hims & Hers Health
FDA cited Hims for marketing compounded semaglutide as equivalent to FDA-approved Wegovy, despite compounded products not being FDA-evaluated for purity, potency, or safety.
Action: If currently using Hims compounded semaglutide, talk to your prescriber about transitioning to FDA-approved Wegovy if eligible. Compounded products carry unverified purity risks.
Source: FDA.govSubject: All GLP-1 manufacturers
FDA reminded clinicians and consumers of the boxed warning for thyroid C-cell tumors in animal studies. Real-world surveillance suggests low absolute risk but ongoing monitoring required.
Action: Tell your prescriber about any family history of thyroid cancer before starting any GLP-1. Periodic neck exams during treatment standard of care.
Source: FDA.govUpdated continuously as FDA actions and court filings are issued. Last refreshed May 30, 2026. Most affiliate review sites suppress safety information that could deter conversion. Surfacing it openly is editorial position — same reason we publish methodology and editor bylines.
Want broader context? How we evaluate safety · Our medical reviewers